Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Lancet Reg Health Southeast Asia. 2022 Nov 25;9:100118. doi: 10.1016/j.lansea.2022.100118

Table 2.

Major presentations of patients with melioidosis

Presentation All (n=1352) Bacteraemia Septic shock Died at one month Died at one year
Lung infection 565 (41·8%) 430 (76·1%) 268 (47·4%) 200 (35·7%) 253 (45·8%)
Skin/soft tissue infection 307 (22·7%) 165 (53·8%) 61 (19·9%) 42 (13·8%) 57 (19·1%)
Bacteremia without focus 275 (20·3%) 275 (100·0%) 85 (30·9%) 77 (28·2%) 100 (37·3%)
Intra-abdominal infection 215 (15·9%) 184 (85·6%) 51 (23·7%) 34 (16·0%) 47 (22·5%)
Genitourinary tract infection 173 (12·8%) 153 (88·4%) 67 (38·7%) 49 (28·3%) 72 (42·4%)
Septic arthritis 108 (8·0%) 87 (80·6%) 30 (27·8%) 11 (10·3%) 23 (21·9%)
Osteomyelitis 11 (0·8%) 6 (54·6%) 2 (18·2%) 0 (0·0%) 2 (18·2%)
Neurological infection 11 (0·8%) 7 (63·6%) 3 (27·3%) 1 (9·1%) 3 (27·3%)

Sum of the first column exceeds total number of patients as some patients had more than one presentation.

Septic shock is defined as a requirement of inotropic or vasopressor agents during the hospitalization.

Vital status was missing for seven patients at one month and 30 patients at one year.